

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Blumenthal
Date of last notice	31 March 2017 & 27 July 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> (an entity controlled by Mr Blumenthal)
Date of change	23 July 2018

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct (Adam Blumenthal)</p> <p>1 fully paid ordinary share (<i>subject to escrow until 20 October 2018</i>)</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>4,000,000 fully paid ordinary shares (<i>subject to escrow until 20 October 2018</i>)</p> <p>750,000 performance rights subject to vesting conditions (<i>issued 14 December 2015</i>) (<i>subject to escrow until 20 October 2018</i>)</p> <p>1,500,000 performance rights subject to vesting conditions (<i>issued 27 July 2017 following grant of shareholder approval obtained on this date</i>)</p>
<p>Class</p>	<p>Fully paid ordinary shares and performance rights</p>
<p>Number acquired</p>	<p>1,500,000 fully paid ordinary shares (<i>issued on vesting of performance rights</i>)</p>
<p>Number disposed</p>	<p>1,500,000 performance rights (<i>vested into shares</i>)</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil – vesting of Performance Rights on achievement of Milestones (<i>as per announcement lodged with ASX on 23 July 2018</i>)</p>
<p>No. of securities held after change</p>	<p>Direct (Adam Blumenthal)</p> <p>1 fully paid ordinary share (<i>subject to escrow until 20 October 2018</i>)</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>4,000,000 fully paid ordinary shares (<i>subject to escrow until 20 October 2018</i>).</p> <p>1,500,000 fully paid ordinary shares</p> <p>750,000 performance rights subject to vesting conditions (<i>issued 14 December 2015</i>) (<i>subject to escrow until 20 October 2018</i>)</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Shares issued on vesting and conversion of performance rights that were issued on 27 July 2017 following receipt of shareholder approval at General Meeting held 27 July 2017 as detailed in the Notice of Meeting lodged with ASX on 26 June 2017. The Performance Rights vested upon satisfaction of Milestones as per announcement lodged with ASX on 23 July 2018.</p>
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.